How Has The Antispasmodics Drugs Market Size Evolved In Recent Years?
The antispasmodics drugs market has seen considerable growth due to a variety of factors.
• The market size for antispasmodic drugs has seen significant growth in the last few years. The market is projected to expand from $13.76 billion in 2024 to $15.07 billion in 2025, with a compound annual growth rate (CAGR) of 9.5%. The growth in the past period has been influenced by factors such as an increase in spasmodic conditions, progress in medical research, an expanding ageing population, lifestyle changes, and developments in diagnosis.
What Are The Predictions for The Antispasmodics Drugs Template Market?
The Antispasmodics Drugs market is expected to maintain its strong growth trajectory in upcoming years.
• The market size of antispasmodic drugs is anticipated to witness substantial growth in the upcoming years. It is projected to reach $21.91 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 9.8%.
The projected growth during the forecast period is largely attributable to factors like increased healthcare spending, personalized medicine, the surge in global population size, emerging markets, as well as ongoing clinical trials and research. The significant trends playing a role in this forecast period comprise the expanding usage of antispasmodics, development of healthcare infrastructure, advancement in drug development, increased awareness and diagnosis, as well as a preference towards non-invasive treatment options.
Which Drivers Are Accelerating Growth In The Antispasmodics Drugs Market?
The growth of the antispasmodic drug market is anticipated to be driven by a rise in the elderly population. Individuals aged 65 and above are typically categorized as elderly and are likely to have multiple physical and psychological health complications. Antispasmodic medications can be particularly beneficial for these individuals in managing symptoms associated with conditions that lead to muscle spasms or cramping. They may also be used for conditions such as irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), interstitial cystitis, and uterine cramping. For example, the World Health Organization (WHO), a Switzerland-based global public health body, predicted in October 2022 that the worldwide population of individuals aged 60 and more will reach 1.4 billion by 2030. By 2050, this age group is expected to double to 2.1 billion. The population of people aged 80 and above is forecasted to significantly increase by 2050, totaling 426 million. Consequently, the increase in the elderly population will bolster the antispasmodic drug market.
What Are The Core Segments Of The Global Antispasmodics Drugs Market?
The antispasmodics drugs market covered in this report is segmented –
1) By Drug: Dicyclomine Hydrochloride, Loperamide Hydrochloride, Other Drugs
2) By Indication: Irritable Bowel Syndrome, Stomach Cramps, Other Indications
3) By Route Of Administration: Oral, Parenteral, Other Modes Of Administrations
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Dicyclomine Hydrochloride: Oral Tablets, Injectable Formulations
2) By Loperamide Hydrochloride: Oral Tablets, Liquid Formulations
3) By Other Drugs: Hyoscine Butylbromide (Scopolamine), Peppermint Oil, Atropine, Other Antispasmodics
Pre-Book The Antispasmodics Drugs Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Trends Are Reshaping The Antispasmodics Drugs Market Size?
A rising trend in the antispasmodic drugs market is product innovation, with dominant firms channeling efforts into creating novel solutions to solidify their market standing. For instance, Ardelyx Inc., a biopharmaceutical corporation based in the United States, unveiled IBSRELA, an NHE-3 inhibitor intended to manage irritable bowel syndrome with constipation (IBS-C) in April 2022. This pioneering therapeutic alternative with a unique mechanism of action offers impressive effectiveness in alleviating constipation and various abdominal symptoms typical of IBS-C patients, as demonstrated in Phase 3 clinical trials.
Who Are the Key Players In The Antispasmodics Drugs Market?
Major companies operating in the antispasmodics drugs market include:
• Daiichi Sankyo Company Limited
• Fresenius Kabi AG
• Hikma Pharmaceuticals plc
• Johnson & Johnson Services Inc.
• Pfizer Inc.
• Shanghai Fosun Pharmaceutical Co. Ltd.
• Takeda Pharmaceutical Company Limited
• Akorn Inc.
• Aurobindo Pharma Limited
• Lannett Company Inc.
• Nexus Pharmaceuticals Inc.
• Actiza Pharmaceutical Private Limited
• Blue Cross Laboratories Pvt. Ltd.
• Dr. Reddy's Laboratories Ltd.
• Lexicare Pharma Pvt. Ltd.
• Solitaire Pharmacia Private Limited
• Strides Pharma Science Limited
• Wellona Pharma Private Limited
• SunGen Pharma LLC
• GlaxoSmithKline plc
• Novartis AG
• Sanofi SA
• AstraZeneca plc
• Merck & Co. Inc.
• Bayer AG
• Teva Pharmaceutical Industries Ltd.
• Endo Pharmaceuticals Inc.
• Sun Pharmaceutical Industries Ltd.
• Cipla Ltd.
• Lupin Ltd.
What Are The Regional Insights Into The Antispasmodics Drugs Market?
North America was the largest region in the antispasmodics drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the antispasmodics drugs market report during the forecast period. The regions covered in the antispasmodics drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
